Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMISO PET Imaging of Hypoxia in HCC Patients
NCT03303469Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 2017
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluoromisonidazole in hepatocellular carcinoma (HCC), sponsored by University of Alabama at Birmingham. Started Oct 2017; status: terminated.
02
Drugs
fluoromisonidazole
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03303469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303469.